Sui W. Ling

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Phase 1 Dose-Escalation Study of [225Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry.

Phase 1 Dose-Escalation Study of [225Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: December 16, 2025

First real-world clinical experience with [177Lu]Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer beyond VISION and TheraP criteria.

First real-world clinical experience with [177Lu]Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer beyond VISION and TheraP criteria.

Journal: European journal of nuclear medicine and molecular imaging

Published: November 01, 2024

Tubarial salivary glands show a low relative contribution to functional salivary gland tissue mass.

Tubarial salivary glands show a low relative contribution to functional salivary gland tissue mass.

Journal: Annals of nuclear medicine

Published: June 11, 2024

Evaluation of the tolerability and safety of [225Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study.

Evaluation of the tolerability and safety of [225Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study.

Journal: BMC cancer

Published: January 10, 2024

Liquid Biopsies for Early Response Evaluation of Radium-223 in Metastatic Prostate Cancer.

Liquid Biopsies for Early Response Evaluation of Radium-223 in Metastatic Prostate Cancer.

Journal: JCO precision oncology

Published: December 07, 2023

Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives.

Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives.

Journal: EJNMMI radiopharmacy and chemistry

Published: July 20, 2023

68Ga-PSMA PET/CT for Response Evaluation of 223Ra Treatment in Metastatic Prostate Cancer.

68Ga-PSMA PET/CT for Response Evaluation of 223Ra Treatment in Metastatic Prostate Cancer.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: January 19, 2023

Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.

Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.

Journal: Pharmaceutics

Published: July 22, 2022

Comparison of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography for Primary Staging of Prostate Cancer: A Systematic Review and Meta-analysis.

Comparison of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography for Primary Staging of Prostate Cancer: A Systematic Review and Meta-analysis.

Journal: European urology open science

Published: August 05, 2021

Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC.

Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC.

Journal: Pharmaceutics

Published: March 30, 2021

A Blended Web-Based Gaming Intervention on Changes in Physical Activity for Overweight and Obese Employees: Influence and Usage in an Experimental Pilot Study.

A Blended Web-Based Gaming Intervention on Changes in Physical Activity for Overweight and Obese Employees: Influence and Usage in an Experimental Pilot Study.

Journal: JMIR serious games

Published: July 28, 2016

Showing 1-11 of 11

Last Updated: 09/26/2026